Related Experiment Video

Updated: Jul 2, 2026

Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector
08:33

Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector

Published on: February 28, 2016

13.8K

Progressive neurodegeneration, motor decline, and premature mortality in aging Ngly1 deficient rats

Lei Zhu1,2, Selina Dwight1,2, William F Mueller3,4

  • 1Grace Science, LLC, Menlo Park, CA, 94025, USA.

Orphanet Journal of Rare Diseases
|February 20, 2026
PubMed
Abstract

No abstract available in PubMed .

Keywords:
CNSMortalityMotor functionNGLY1NGLY1 DeficiencyRare diseases

More Related Videos

Gait Analysis of Age-dependent Motor Impairments in Mice with Neurodegeneration
07:46

Gait Analysis of Age-dependent Motor Impairments in Mice with Neurodegeneration

Published on: June 18, 2018

12.7K
Modeling Age-Associated Neurodegenerative Diseases in Caenorhabditis elegans
07:04

Modeling Age-Associated Neurodegenerative Diseases in Caenorhabditis elegans

Published on: August 15, 2020

5.9K

Related Experiment Videos

Last Updated: Jul 2, 2026

Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector
08:33

Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector

Published on: February 28, 2016

13.8K
Gait Analysis of Age-dependent Motor Impairments in Mice with Neurodegeneration
07:46

Gait Analysis of Age-dependent Motor Impairments in Mice with Neurodegeneration

Published on: June 18, 2018

12.7K
Modeling Age-Associated Neurodegenerative Diseases in Caenorhabditis elegans
07:04

Modeling Age-Associated Neurodegenerative Diseases in Caenorhabditis elegans

Published on: August 15, 2020

5.9K

Related Concept Videos

Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

Articles linked to this work by shared authors, journal, and citation graph.

Natural history of NGLY1 deficiency: motor function & clinical features.

Human molecular genetics·2026

Preclinical pharmacology and safety studies to support an AAV9 NGLY1 gene therapy clinical trial for the treatment of NGLY1 deficiency.

Molecular therapy. Methods & clinical development·2025

The STING pathway drives noninflammatory neurodegeneration in NGLY1 deficiency.

The Journal of experimental medicine·2025

AAV9-NGLY1 gene replacement therapy improves phenotypic and biomarker endpoints in a rat model of NGLY1 Deficiency.

Molecular therapy. Methods & clinical development·2022

Pharmacokinetic, pharmacodynamic, and immunogenic rationale for optimal dosing of pegvaliase, a PEGylated bacterial enzyme, in adult patients with phenylketonuria.

Clinical and translational science·2021

2020 White Paper on Recent Issues in Bioanalysis: Vaccine Assay Validation, qPCR Assay Validation, QC for CAR-T Flow Cytometry, NAb Assay Harmonization and ELISpot Validation (Part 3 - Recommendations on Immunogenicity Assay Strategies, NAb Assays, Biosimilars and FDA/EMA Immunogenicity Guidance/Guideline, Gene & Cell Therapy and Vaccine Assays).

Bioanalysis·2021

Lower mitochondrial DNA copy number in ATTRV50M Swedish carriers.

Orphanet journal of rare diseases·2026

Longitudinal assessment of the retinal phenotype in patients with Fabry disease undergoing continuous enzyme replacement and/or chaperone therapy.

Orphanet journal of rare diseases·2026

Real world experience of carglumic acid for methylmalonic and propionic acidurias: the second interim analysis of the multicentre observational PROTECT study.

Orphanet journal of rare diseases·2026

Clinical management of metachromatic leukodystrophy cases identified in the German and Austrian Newborn screening pilots.

Orphanet journal of rare diseases·2026

Hyperphagia in Prader-Willi syndrome: linking hypothalamic dysfunction to clinical assessment and management across the lifespan.

Orphanet journal of rare diseases·2026

Real world data from the Heidelberg Registry of Chronic Singultus (HeReChroS).

Orphanet journal of rare diseases·2026

Monoamine receptors of intrinsic spinal neurons and their role in mammalian locomotor control: from physiology to pathology.

Reviews in the neurosciences·2026

Nanotechnology meets neurodegeneration: restoring lysosomal function with nanovectors.

Expert opinion on drug delivery·2026

Neurofibromatosis Type 1: An Imaging Review of Multisystem Manifestations in Children.

Journal of neuroimaging : official journal of the American Society of Neuroimaging·2026

Altered oligodendroglial cell development and increased myelination in SCN2A gain-of-function-linked epilepsy.

Acta neuropathologica communications·2026

Elevated atherogenic index of plasma in multiple sclerosis: association with metabolic profile in a cross-sectional study.

BMC neurology·2026

Combined pharmacological targeting of NAD+ metabolism preserves central and peripheral axons in an ex vivo model of Wallerian degeneration.

Experimental neurology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us